- Viagra
- Sildenafil Citrate (TP)
- Sildenafil Citrate TEVA
- Sildenafil Citrate (GS)
- Tadalafil TEVA
- Tadalafil ACCORD
- Tadalafil DAILY
- Vardenafil TEVA
- Vardenafil ZYDUS
- Cialis
Stem cell scarring aids recovery from spinal cord injury
2013-11-03
|
Spinal cord injuries sever nerve fibres that conduct signals between the brain and the rest of the body, causing various degrees of paralysis depending on the site and extent of the injury. Functional impairment is often permanent, since the cut nerve fibres do not grow back. The lack of regeneration has been attributed to a blockage from scar tissue that forms at the lesion. It has therefore been suggested that the nerve fibres could regenerate and that recovery could improve if scar formation is inhibited, and many proposed therapeutic strategies have been designed around this concept.
In the present study, the researchers focused on spinal cord stem cells, which are one of the main sources of the scar tissue that is formed after spinal cord injury. They found that when blocking scar formation by preventing the stem cells from forming new cells after an injury, the injury gradually expanded, and more nerve fibres were severed. They also observed that more spinal cord nerve cells died in these mice compared to mice with intact stem cell function, which were able to form normal scar tissue.
"It turned out that scarring from stem cells was necessary for stabilising the injury and preventing it from spreading," says principal investigator Professor Jonas Frisén at the Department of Cell and Molecular Biology. "Scar tissue also facilitated the survival of damaged nerve cells. Our results suggest that more rather than less stem cell scarring could limit the consequences of a spinal cord injury."
According to earlier animal studies, recovery can be improved by transplanting stem cells to the injured spinal cord. The new findings suggest that stimulating the spinal cord's own stem cells could offer an alternative to cell transplantation.
The study was supported by grants from the Swedish Research Council, the Swedish Cancer Society, the Tobias Foundation, AFA Insurance, the Strategic Research Programme in Stem Cell Research and Regenerative Medicine (StratRegen) at Karolinska Institutet and the Knut and Alice Wallenberg Foundation.